

# Aerocrine

Press release  
29 June, 2012

## **Positive outcome for Aerocrine in patent proceedings against Medisoft in Belgium**

**SOLNA, Sweden - 29 June, 2012 - Aerocrine AB (OMX Nordic Exchange: AERO) today announced the positive outcome of its complaint against Medisoft S.A. filed at the Liège Commercial Court, Belgium.**

On 14 October 2011, Aerocrine started infringement proceedings against the Belgian company Medisoft S.A. before the Liège Commercial Court, on the basis of four of Aerocrine's patents. Medisoft challenged both infringement and the validity of the patents as part of its defense. The oral hearings on the merits took place during the spring 2012.

Yesterday the Court upheld Aerocrine's patents EP 1,439,781 and EP 1,661,514 as valid and ruled that both the Medisoft Hyp'Air FeNO and Hyp'Air FeNO+ devices infringe these patents. Accordingly, Medisoft which is headquartered in Belgium, will be immediately prohibited as from service of the decision, from manufacturing, using, maintaining, detaining and offering for sale any Hyp'Air products.

The Court also invalidated Aerocrine's earliest patents EP 0,606,351 and EP 0,724,723 for Belgium. These patents expire in 2012 and 2014.

The judgment may be appealed by both parties.

### **For more information, contact:**

Scott Myers, CEO, Aerocrine AB, +46 768 788 379

Mats Carlson, Chief Technology Officer, Aerocrine, AB +46 8 629 07 83

### **About Aerocrine**

*Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in technology to monitor and manage airway inflammation, Aerocrine markets NIOX MINO® and NIOX Flex®. Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the U.S., Germany and the U.K. Aerocrine shares were listed on the Stockholm Stock Exchange in 2007.*

Aerocrine may be required to disclose the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 8:00 a.m. on June 29, 2012.
---